Roche Says Experimental MS Pill Cuts Relapses 55% in Late-Stage Trials
Roche said late-stage trial data showed its experimental fenebrutinib reduced markers of chronic brain inflammation and delivered broader disease control than comparator treatments in patients with relapsing and primary progressive multiple sclerosis.